Skip to main content

Warnex Inks Pharmacogenetics Services Deal with Schering-Plough Canada

NEW YORK (GenomeWeb News) - Warnex Medical Laboratories will develop several new pharmacogenetic assays for Schering-Plough Canada, Warnex said last week.
 
Under the agreement, Warnex said it will supply pharmacogenetic and molecular biology services for Schering-Plough’s clinical trials for cancer and infectious disease therapeutics.
 
Warnex said the company is using its services to identify patients who are more likely to respond to a treatment or who are less likely to have an adverse event.
 
Financial terms of the agreement were not released.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.